![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Research Insight
Teva announced new data from the Phase III placebo-controlled and randomized First Time Use of SD-809 in HuntingtonDisease
Teva Pharmaceutical Industries Ltd., announced new data from the Phase III placebo-controlled and randomized First Time Use of SD-809 in HuntingtonDisease (First-HD) study evaluating...
Research Insight
IMS Health Study: U.S. Drug Spending Growth Reaches 8.5 Percent in 2015
Total spending on medicines in the U.S. reached $310 billion in 2015 on an estimated net price basis, up 8.5 percent from the previous...
Research Insight
Amgen, UCB Present reports on comparing Romosozumab With Teriparatide
In Phase 3 Open-Label STRUCTURE Study Postmenopausal Women With Osteoporosis Transitioning From Oral Bisphosphonates to Romosozumab Experienced Consistent and Significant Gains in Bone Mass...
Research Insight
The diabetes drug pioglitazone is associated with an increased risk of bladder cancer
The diabetes drug pioglitazone is associated with an increased risk of bladder cancer, finds a study published by The BMJ today. The findings suggest...
Research Insight
Penn Study Describes the Molecular Cause of Common Cerebrovascular Disease
Cerebral cavernous malformations (CCMs) are clusters of dilated, thin-walled blood vessels in the brain that can cause stroke and seizures, yet exactly how they...
Research Insight
FDA approves new indication for Novartis drug Afinitor
Novartis announced that the United States Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated,...
Research Insight
Studies Show Ixekizumab Improved Work Productivity for Patients with Moderate-to-Severe Plaque Psoriasis
Eli Lilly and Company announced that JAMA Dermatology has published detailed results from three pivotal Phase 3 trials that evaluated the effect of ixekizumab...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read